Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.8552W HIGH $9.28
Volume
2.60 K
Value Traded
318.02 K
Short % Float
2.89%
-5.55%Week
+10.97%1 Month
+17.71%3 Month
+125.89%6 Month
+95.67%5 Year
-65.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
100.39 M
EPS (TTM)
-0.73
P/E Ratio
-
Ent. Value
100.72 M
Total Shares
14.97 M
Float Shares
8.75 M
Insiders
41.60%
Institutions
16.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CPIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Cumberland Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cumberland Pharmaceuticals Inc.
763Total events
7Upcoming
273Tier-1 (high impact)
2010 to 2026Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Interim Analysis
Subscribe to view catalyst details
Event history 50
▲Topline ReadoutIfetrobanClinical Data
Phase 2 cancer metastasis study met primary safety objective; secondary endpoint not significant
Cancer metastasis prevention (Stage I-III malignant solid tumors)source ↗
▲Primary Endpoint MetIfetrobanClinical Data
Phase 2 cancer metastasis study met primary safety/feasibility objective
Cancer metastasis prevention (Stage I-III malignant solid tumors)source ↗
▲Secondary Endpoint DataIfetrobanClinical Data
Secondary endpoint metastasis recurrence data reported
Cancer metastasis prevention (Stage I-III malignant solid tumors)source ↗
▲Quarterly UpdateCorporate
Board authorized open-market share repurchase program of up to $5 million
▲Primary Endpoint MetIfetrobanClinical Data
Pilot study results suggest potential to block cancer metastasis; favorable trend in fewer deaths due to metastatic disease
Cancer Metastasissource ↗
●Enrollment UpdateIfetrobanTrial
Phase II study of ifetroban in IPF actively enrolling
Idiopathic Pulmonary Fibrosissource ↗
▲Full ResultsIfetrobanClinical Data
Results of Pilot Study of ifetroban in high-risk solid tumors announced
Cancer Metastasissource ↗
◆FDA Feedback ReceivedIfetrobanFDA Meeting
Interactions with FDA underway regarding study results and approval requirements
Duchenne Muscular Dystrophy Cardiomyopathysource ↗
▲Interim AnalysisIfetrobanTrial
Favorable interim safety findings announced for ifetroban in IPF
Idiopathic Pulmonary Fibrosissource ↗
▲AcquiredCorporate
Apotex completes strategic transaction to integrate Cumberland's U.S. branded businesses
◆AcquisitionCorporate
Apotex acquired Cumberland's FDA-approved brands for $100M cash plus $11M
▲Primary Endpoint MetIfetrobanClinical Data
Breakthrough results in Phase II study of ifetroban for DMD cardiomyopathy
Duchenne Muscular Dystrophy Cardiomyopathysource ↗
◆FDA Feedback ReceivedIfetrobanFDA Meeting
Interactions with FDA regarding study results and approval requirements
Duchenne Muscular Dystrophy Cardiomyopathysource ↗
●Enrollment UpdateIfetrobanTrial
Phase II study for IPF actively enrolling
Idiopathic Pulmonary Fibrosissource ↗
▲Interim AnalysisIfetrobanTrial
Favorable interim safety findings announced for ifetroban in IPF
Idiopathic Pulmonary Fibrosissource ↗
▲Full ResultsIfetrobanClinical Data
Results of Pilot Study of ifetroban in cancer metastasis announced
Cancer Metastasissource ↗
▲Poster PresentationIfetrobanPresentation
Updated FIGHT DMD trial results presented at PPMD annual conference
Duchenne muscular dystrophy cardiomyopathysource ↗
◆Full ResultsIfetrobanClinical Data
Updated results from FIGHT DMD trial including 36-month safety and biomarker data
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
▲Long Term DataIfetrobanClinical Data
36-month safety data from open-label extension
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
◆Oral PresentationIfetrobanPresentation
Updated FIGHT DMD trial results presented at PPMD annual conference
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
▲Biomarker DataIfetrobanClinical Data
Novel blood biomarker results: MYL3, MYOD1, FGF16, TSPAN7
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
▲Primary Endpoint MetIfetrobanClinical Data
Phase 2a trial of ifetroban met primary safety endpoint
high-risk solid tumorssource ↗
▲Secondary Endpoint DataIfetrobanClinical Data
Secondary endpoint showed fewer deaths due to metastasis in ifetroban arm (p=0.037)
high-risk solid tumorssource ↗
▲Oral PresentationIfetrobanPresentation
Updated FIGHT DMD results presented at PPMD Conference
Duchenne muscular dystrophy-associated cardiomyopathysource ↗
▲Product LaunchVibativApprovedPost-Market
Launch of Vibativ in China
serious bacterial infections including HABP/VABP and cSSSIsource ↗
▲NMPA NDA ApprovalVibativApprovedEx-US Regulatory
NMPA approval of Vibativ in China
serious bacterial infections including HABP/VABP and cSSSIsource ↗
▲Partnership / LicenseVibativApprovedCorporate
Strategic partnership with SciClone Pharmaceuticals for China rights
serious bacterial infectionssource ↗
▲Partnership / LicenseCorporate
Strategic Transaction with Apotex to sell FDA-approved brands for $100M
◆FDA Feedback ReceivedIfetrobanFDA Meeting
Discussions with FDA underway regarding DMD study results and approval requirements
Duchenne muscular dystrophy (DMD) cardiomyopathysource ↗
▲Enrollment CompleteIfetrobanTrial
Enrollment completed in Phase II ifetroban SSc study
Systemic Sclerosis (SSc)source ↗
◆Partnership / LicenseCorporate
Apotex to acquire Cumberland's branded pharmaceuticals for $100M
▲Primary Endpoint MetIfetrobanClinical Data
Breakthrough results in Phase II study of ifetroban in DMD cardiomyopathy
cardiomyopathy associated with Duchenne muscular dystrophysource ↗
◆FDA Feedback ReceivedIfetrobanFDA Meeting
FDA interactions underway for ifetroban DMD program
cardiomyopathy associated with Duchenne muscular dystrophysource ↗
▲Enrollment CompleteIfetrobanTrial
Enrollment completed in Phase II ifetroban study for SSc
Systemic Sclerosis (scleroderma)source ↗
●Enrollment UpdateIfetrobanTrial
Enrollment well underway in Phase II ifetroban IPF study
Idiopathic Pulmonary Fibrosissource ↗
▲Label ExpansionCaldolorApprovedFDA Decision
FDA approval for expanded indication of Caldolor to include management of postoperative pain
postoperative painsource ↗
▲Product LaunchCaldolorApprovedPost-Market
Launch of new brand website for Caldolor highlighting expanded indication
postoperative painsource ↗
▲Product LaunchSancusoApprovedPost-Market
Cumberland Pharmaceuticals launches new Sancuso website with educational resources
chemotherapy-induced nausea and vomitingsource ↗
▲Product LaunchTaliciaApprovedPost-Market
U.S. national sales promotion launch of Talicia
Helicobacter pylori infectionsource ↗
▲Fast Track DesignationIfetrobanDesignation
FDA grants Fast Track Designation for ifetroban in DMD heart disease
Duchenne muscular dystrophy heart diseasesource ↗
▲Product LaunchTaliciaApprovedPost-Market
Full sales and operational launch of Talicia by THI
H. pylori infectionsource ↗
▲Fast Track DesignationIfetrobanDesignation
Ifetroban receives Fast Track Designation from FDA
Duchenne muscular dystrophy (DMD) heart diseasesource ↗
▲Enrollment CompleteIfetrobanTrial
Enrollment completed in Phase II SSc study
Systemic Sclerosis (SSc)source ↗
▲Product LaunchCaldolorApprovedPost-Market
Caldolor J-code J1741 associated with CMS reimbursement price
pain and fever managementsource ↗
Past FDA Catalysts and PDUFA Decisions
How CPIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-23 | Caldolor (ibuprofen) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$260M
Pipeline Value
$40M
Commercial Value
Undervalued
Valuation Signal
3
Drugs Scored
3.9x
rNPV / MCap
Top 27%
Micro Cap(rank 178 of 658)
Percentile Rank
Cumberland Pharmaceuticals Inc. carries a moderate pipeline score (45/100), with $1.0B risk-adjusted pipeline value, led by Atorvastatin in Hypercholesterolemia (Phase 2), across $72B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $39.9M x 1.0 = $40M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Product - Sancuso | $12M | $9M | +28.8% |
| Product - Kristalose | $10M | $13M | -26% |
| Talicia | $8M | - | - |
| Product - Vibativ | $5M | $9M | -43.4% |
| Caldolor | $4M | $6M | -24.1% |
| Acetadote | $0M | $0M | -13.3% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Atorvastatin Small moleculeCompletedNCT03611010 | Hypercholesterolemia | Phase 2 | COMPLETED | 40 | Feb 24, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every CPIX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ifetroban Fast TrackOrphanRare Pediatric | cancer metastasis prevention | Phase 2a | 2026-06-02 | deaths due to metastasis placebo: 3; deaths due to metastasis ifetroban: 0; distant metastatic recurrence placebo: 50; distant metastatic recurrence ifetroban: 17; p value deaths: 0.037; p value recurrence: 0.091Read More | Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer MetastasisRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Galante Joseph CDirector | Grant/Award | 1,800 63,656 held | $2.80 | 03/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CPIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.4 % (300 %) | 3.26 M | 503.15 K | -9.04% ( -50.00 K) |
CPIX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CPIX ranks across every disease it competes in
Competitive Position is a premium feature
See how CPIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCPIX News
CPIXCUMBERLAND PHARMACEUTICALS OUTLINES STRATEGIC TRANSFORMATION AND REAFFIRMS COMMITMENT TO NASHVILLE’S LIFE SCIENCES COMMUNITY
Cumberland Pharmaceuticals has announced a strategic transformation aimed at enhancing its focus on clinical-stage development. CEO A.J. Kazimi emphasized the company's commitment to addressing unmet medical needs while supporting Nashville's life sciences ecosystem. The company is advancing its pipeline, particularly with ifetroban, and has divested its commercial pharmaceutical brands to strengthen its financial resources for ongoing clinical programs.
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
Cumberland Pharmaceuticals reported its Q2 2026 financial results, highlighting a successful $100 million strategic transaction with Apotex Health. The company returned capital to shareholders via a special dividend while maintaining resources to advance its development pipeline. Despite a net loss of $4.1 million, Cumberland continues to focus on differentiated medicines for rare diseases.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
Cumberland Pharmaceuticals Inc. will announce its Q2 2026 financial results and provide a company update on August 4, 2026. A conference call is scheduled for 4:30 p.m. Eastern Time, where participants can register to join. The company focuses on developing innovative products for rare diseases and is advancing several late-stage clinical programs.
Read more →CPIX▲ +12%on this news· ran to +31% by day 3
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
Cumberland Pharmaceuticals has declared a special cash dividend of $1.50 per share, payable on July 31, 2026. This decision follows a strategic transaction with Apotex Health, which provided Cumberland with $100 million in cash. The company is also focusing on developing ifetroban for serious diseases, having received multiple FDA designations for its clinical programs.
Read more →CPIX▲ +12%on this news· ran to +31% by day 3
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
Cumberland Pharmaceuticals has declared a special cash dividend of $1.50 per share, payable on July 31, 2026. This decision follows a strategic transaction with Apotex Health, which provided Cumberland with $100 million in cash. The company continues to focus on its clinical pipeline, particularly the development of ifetroban for various serious diseases, with promising results in ongoing studies.
Read more →CPIX▲ +10%on this news
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
Cumberland Pharmaceuticals has completed a $100 million transaction with Apotex, enhancing its focus on rare disease treatments. The agreement, supported by over 99% of shareholders, allows Cumberland to concentrate on developing ifetroban, a drug targeting several serious conditions. The company retains its innovative product portfolio and majority ownership in Cumberland Emerging Technologies.
Read more →CPIX▲ +10%on this news
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
Apotex Health Corp. has successfully completed a strategic transaction with Cumberland Pharmaceuticals, integrating Cumberland's U.S. branded businesses into its operations. This acquisition enhances Apotex's portfolio with established medicines in areas such as oncology and infectious disease. The leadership of both companies expressed optimism about improving patient care and expanding access to high-quality treatments.
Read more →CPIX▲ +12.3%on this newsshared move
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals presented updated results from its Phase 2 FIGHT DMD trial at the PPMD conference, showcasing ifetroban's potential in treating cardiac issues associated with Duchenne muscular dystrophy (DMD). The findings highlighted improvements in cardiac function and biomarkers of heart damage, reinforcing the drug's cardioprotective effects. The trial results are significant as they address a critical gap in DMD treatment options.
Read more →CPIXCumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
Cumberland Pharmaceuticals and Vanderbilt Health announced positive results from a Phase 2a clinical trial of ifetroban, aimed at preventing cancer metastasis in high-risk solid tumor patients. The trial met its primary endpoint for safety and showed promising efficacy, with fewer deaths due to metastasis in the ifetroban group compared to placebo. These findings support the continued development of ifetroban as a potential therapy for metastasis prevention.
Read more →CPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
Cumberland Pharmaceuticals has launched its antibiotic Vibativ (telavancin) in China through a partnership with SciClone Pharmaceuticals. This launch follows regulatory approval from China's National Medical Products Administration, allowing SciClone to promote and distribute the drug in a significant pharmaceutical market. Vibativ is designed to treat serious bacterial infections, including those caused by resistant strains.
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. reported a 5% increase in net revenues to $9.1 million for Q1 2026, alongside a strategic transaction with Apotex to enhance its focus on high-value product candidates. The company is advancing its pipeline, particularly the ifetroban candidate, which has received Fast Track Designation from the FDA. Despite these positive developments, Cumberland reported a net loss of $3.3 million for the quarter.
Read more →CPIXCUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS COMPANY UPDATE
Cumberland Pharmaceuticals reported its Q1 2026 financial results, including net revenues of $9.1 million, representing a 5% increase from the previous year. The company has entered a strategic transaction with Apotex to sell its portfolio of FDA-approved brands for $100 million, aiming to refocus on high-value product candidates. Notably, the company received Fast Track Designation for its promising product ifetroban, aimed at treating Duchenne muscular dystrophy. Despite these advances, Cumberland posted a net loss of $3.3 million for the quarter.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will announce its Q1 2026 financial results on May 5, 2026. The announcement will be followed by a conference call at 4:30 p.m. ET to discuss the results and provide a company update. Cumberland focuses on specialty pharmaceuticals, particularly in acute care, gastroenterology, and oncology.
Read more →CPIX▲ +27.9%on this newsshared move
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
Cumberland Pharmaceuticals has announced a strategic agreement with Apotex to integrate their branded U.S. businesses. The deal, valued at $100 million, will allow Cumberland to focus on its pipeline of orphan drug candidates while Apotex aims to enhance patient care. The transaction is pending shareholder approval.
Read more →CPIXCUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
Cumberland Pharmaceuticals has received FDA approval for an expanded indication of its Caldolor® (ibuprofen) Injection, now including postoperative pain management. This approval is accompanied by the launch of a new website aimed at healthcare professionals, emphasizing non-opioid pain management strategies. The updated labeling positions Caldolor as a versatile option for both adult and pediatric patients.
Read more →CPIXCumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
Cumberland Pharmaceuticals has launched a new website for its Sancuso® product, aimed at providing educational resources related to chemotherapy-induced nausea and vomiting (CINV). The site offers comprehensive product information, healthcare provider resources, and patient education. Sancuso is the only FDA-approved transdermal patch for CINV prevention, delivering medication for up to five days.
Read more →CPIX▼ -19.9%on this news
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland Pharmaceuticals reported a 31% increase in fourth-quarter revenue for 2025, totaling $13.7 million. The company achieved an 18% increase in annual revenue, reaching $44.5 million. Highlights include successful international product launches, positive clinical trial results for ifetroban in DMD, and the establishment of a permanent reimbursement code for Caldolor. Despite a net loss, the company shows strong growth potential.
Read more →CPIX▼ -5.4%on this news· ran to -28% by day 3shared move
Document CUMBERLAND PHARMACEUTICALS REPORTS 31.1% FOURTH QUARTER 2025 REVENUE GROWTH Cumberland to highlight 2025 financial, international, portfolio and clinical progress NASHVILLE, Tenn. (Tuesday
Cumberland Pharmaceuticals Inc. reported a 31.1% increase in fourth quarter 2025 revenue, totaling $13.7 million. The company achieved full-year net revenues of $44.5 million, up 18% from the prior year, alongside a reduced net loss of $2.9 million. Key highlights include substantial international expansion, new product approvals, and successful clinical trial results for the drug ifetroban, targeted for Duchenne muscular dystrophy. Additionally, Caldolor's new permanent J-code is expected to enhance its accessibility in clinical settings.
Read more →CPIXCUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
Cumberland Pharmaceuticals has launched a national sales promotion for Talicia®, an FDA-approved treatment for H. pylori infections. This initiative follows a co-commercialization agreement with RedHill Biopharma and aims to enhance prescription growth. Talicia is recognized as a first-line treatment and is patent protected until 2042, positioning it favorably in the market.
Read more →CPIXCUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals Inc. will announce its 2025 financial results on March 3, 2026, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results and provide a company update. The company focuses on developing products for acute care, gastroenterology, and oncology.
Read more →About Cumberland Pharmaceuticals Inc.
Headquarters1600 WEST END AVENUE, NASHVILLE,, TN, 37203
BIOPHARMAWATCH ELITE PLUS
Trade the next CPIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime